- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03211286
Effect of Intravenous Tranexamic Acid on Reduction of Blood Losses in Hip Fracture Patients
Effect of Intravenous Tranexamic Acid on Reduction of Blood Losses in Hip Fracture Patients. A Randomized, Controlled, Double-blind Study
Studies have shown that hip fractures have a significant perioperative blood loss. Postoperative anaemia is associated with a higher morbidity and mortality.
Tranexamic acid is a safe and effective antifibrinolytic widely used to reduce blood loss in other forms of orthopaedic surgery and in traumatized patients. However, evidence on the effectiveness of TXA in lower extremity fracture care is more limited.
Hip fractures represent a common orthopedic injury in a fragile patient population that often necessitates post-operative blood transfusion thereby putting the patient at additional risk of complications.
The goal of this study is to assess if the use of tranexamic acid in patients with hip fractures will result in a reduction in blood losses and blood transfusion rates.
Our hypothesis is that by providing intravenous TXA at the time of surgery will decrease the amount of preoperative and intraoperative bleeding thereby leading to a decreased need for postoperative transfusion.
This a double blinded, placebo controlled, therapeutic trial in which the patients will be randomized to receive TXA or a placebo (saline solution). Treatment will be administered pre-operatively as well as at the time of surgical incision. The primary outcome will be need for blood transfusion. Secondary outcomes will include calculated perioperative blood loss, length of stay, and rate of thromboembolic events, and 90 day mortality.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Candidates for the study will be consecutive patients with a diagnosis of hip fractures treated at our center. All patients with hip fracture meeting inclusion criteria will be recruited for enrollment into the study. Informed consent will be obtained from the patient prior to randomization.
At that time, each patient will be randomized into one of two groups by a independent staff using computer generated randomization and allocation concealment. The two patient groups will include:
- Study group: 1g of intravenous tranexamic acid at the time of surgical incision.
- Control group: placebo injection (saline solution) at the time of surgical incision.
Both patients and the treating surgeons will be blinded with regard to placebo vs. treatment until completion of the study.
Patients will be treated surgically with a long trochanteric femoral nail (TFN) or hemiarthroplasty.
Blood transfusion criteria will remain consistent with hospital standards (Hb<8 g/dL or >9 g/dL if symptomatic anemia). Total number of blood transfusions received will be documented upon patient discharge.
Deep vein thrombosis (DVT) prophylaxis will remain consistent with hospital standards (subcutaneous heparin from admission until 12 hours prior to surgery and beginning 6 hours after surgery). After discharge, .....
Patients will be followed at regular intervals (1mo, 3mo, and at least 6mo) and at each time point the patient will be asked to report any adverse events (DVT, PT, Stroke, myocardial infarction, infection, hospitalization). Diagnostic studies to assess for thromboembolic events (i.e. DVT, pulmonary embolism (PE), and stroke) will be ordered only if the patient develops clinical signs or symptoms that justify their use.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Alicante
-
Elda, Alicante, Spain, 03600
- Elda University Hospital
-
Elda, Alicante, Spain, 03600
- Hospital Universitario de Elda
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- consecutive patients with a diagnosis of hip fractures treated at our hospital by any surgical procedureExclusion Criteria:
- Age over 60 years
Exclusion Criteria:
- ASA IV
- Concomitant fracture
- Refusal to receive blood products
- Preoperative anemia needing blood transfusion before surgery
- Severe comorbidity (cancer, severe pulmonary disease)
- Allergy for tranexamic acid.
- History of acute thromboembolic event (Deep Vein Thrombosis, Pulmonary Embolism, Stroke)
- Coagulopathy (INR > 1.4)
- Myocardial infarction in the previous 12 months
- Coronary stents
- Renal function impairment (serum creatinine > 2 mg/dL or creatinine clearance <30 mL/min),) or kidney transplant
- Platelet antiaggregant treatment in the week before surgery.
- Severe hepatic dysfunction (AST/ALT >60)
- History of hypercoagulability
- Acquired disturbances of color vision.
- Occurrence intraoperative surgical/medical/anesthetic complications
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: TXA group
Tranexamic acid, a single dose of 1 g intravenous diluted in 100 mL saline solution at the time of surgical incision
|
1 g of intravenous tranexamic acid in 100 mL of saline solution
Other Names:
saline solution 100 mL intravenous
|
Placebo Comparator: Control group
Saline solution, 100 mL intravenous at the time of surgical incision
|
saline solution 100 mL intravenous
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
blood transfusion rate
Time Frame: Hospital stay, from admission to fourth day after surgery
|
Number of patients needing blood transfusion
|
Hospital stay, from admission to fourth day after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Perioperative Blood Loss
Time Frame: Hospital stay, from admission to fourth day after surgery
|
Measurement by serial hemoglobin and hematocrit, and calculation of loss by mathematical formulas
|
Hospital stay, from admission to fourth day after surgery
|
Infection rate
Time Frame: 90 postoperative days
|
surgical and medical (pneumonia, urinary tract, etc)
|
90 postoperative days
|
Thrombotic events
Time Frame: 90 postoperative days
|
Deep Venous Thrombosis, Pulmonary Embolism, Myocardial Infarction, Stroke
|
90 postoperative days
|
Mortality
Time Frame: 90 postoperative days
|
number of deaths
|
90 postoperative days
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Alejandro Lizaur-Utrilla, PHD, MD, Orthopaedic Surgery Department, Elda University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TXA-Hip July2017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anemia
-
SanofiActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)United States, Austria, China, Denmark, Germany, Hungary, Italy, Spain, United Kingdom
-
SanofiTerminatedWarm Autoimmune Hemolytic Anemia (wAIHA)United Kingdom, Belgium, Netherlands, France, United States, Germany, Hungary, Italy
-
Hospital Universitario Dr. Jose E. GonzalezCompletedPernicious Anemia | Megaloblastic Anemia NosMexico
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingSevere Aplastic Anemia | Idiopathic Aplastic Anemia | Moderate Aplastic Anemia Requiring Transfusions
-
Abdelwahed, Mai Mahmoud Mohamed, M.D.UnknownAnemia During PregnancyEgypt
-
University of California, DavisInstituto Mexicano del Seguro Social; Thrasher Research Fund; Mexican National... and other collaboratorsCompleted
-
Incyte CorporationActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)Spain, United States, Austria, Belgium, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Poland, United Kingdom
-
Peking Union Medical College HospitalRecruiting
-
Alexion PharmaceuticalsWithdrawnWarm Autoimmune Hemolytic AnemiaUnited States
Clinical Trials on Tranexamic Acid
-
Icahn School of Medicine at Mount SinaiRecruiting
-
University of LiegeCompletedArthroplasty Complications | Hemorrhage Postoperative | Total Blood LossBelgium
-
London School of Hygiene and Tropical MedicineCompleted
-
Samsung Medical CenterUnknownBleeding | Transfusion Related ComplicationKorea, Republic of
-
Assiut UniversityCompleted
-
Thammasat UniversityCompleted
-
Ferring PharmaceuticalsCompleted
-
Ain Shams UniversityCompleted
-
Aswan University HospitalCompletedCesarean Section ComplicationsEgypt
-
London School of Hygiene and Tropical MedicineRawalpindi Medical CollegeCompletedPregnancy, High RiskPakistan, Zambia